Ignite Creation Date:
2024-05-06 @ 3:47 PM
Last Modification Date:
2024-10-26 @ 1:57 PM
Study NCT ID:
NCT04756271
Status:
COMPLETED
Last Update Posted:
2022-02-09
First Post:
2021-02-13
Brief Title:
Safety and Immunogenicity of Oxford AstraZeneca Vaccine Against COVID-19 Infection
Sponsor:
Zagazig University
Organization:
Zagazig University
Study Overview
Official Title:
Safety and Immunogenicity of Oxford AstraZeneca Vaccine in Zagazig University Hospital Health-care Workers
Status:
COMPLETED
Status Verified Date:
2022-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
After SARS-COV-2 inactivated vaccine authorization for use in different countries including Egypt investigating its immunogenicity safety and efficacy in preventing COVID-19 infection is highly needed In Egypt immunization of HCWs in isolation hospitals by SARS-COV-2 inactivated vaccine is now a national priority Moreover data and reports regarding the application of vaccine are still limited and deficient
Detailed Description:
This study will be conducted at Zagazig University hospital Laboratory work will be implemented at Immunology Research Laboratory at Microbiology and Immunology Department Faculty of Medicine Zagazig University A representative sample will be drawn from healthcare workers HCWs at Zagazig University Hospital Assessment of inclusion and exclusion criteria by history taking Blood samples will be drawn from HCWs by direct venipuncture before the start of immunization and 14 days after immunization The incidence of any adverse reactions after each immunization will be recorded SARS-CoV-2 neutralizing antibodies will be detected by enzyme-linked immunosorbent assay
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None